Basic Science Review
Molecular profiling in primary hyperparathyroidism
Oliwia Anna Segiet MD,
Mariusz Deska MD,
Marek Michalski PhD,
Jacek Gawrychowski MD, PhD,
Romuald Wojnicz MD, PhD,
Corresponding Author
Oliwia Anna Segiet MD
Department of Histology and Embryology, Zabrze, Medical University of Silesia, Katowice, Poland
Corresponding author: O. Segiet, Department of Histology and Embryology in Zabrze, 41-808 Zabrze Rokitnica, ul. Jordana 19, Poland. E-mail: [email protected]Search for more papers by this authorMariusz Deska MD
Chair and Clinical Department of General Surgery, Bytom, Medical University of Silesia, Katowice, Poland
Search for more papers by this authorMarek Michalski PhD
Department of Histology and Embryology, Zabrze, Medical University of Silesia, Katowice, Poland
Search for more papers by this authorJacek Gawrychowski MD, PhD
Chair and Clinical Department of General Surgery, Bytom, Medical University of Silesia, Katowice, Poland
Search for more papers by this authorRomuald Wojnicz MD, PhD
Department of Histology and Embryology, Zabrze, Medical University of Silesia, Katowice, Poland
Search for more papers by this authorOliwia Anna Segiet MD,
Mariusz Deska MD,
Marek Michalski PhD,
Jacek Gawrychowski MD, PhD,
Romuald Wojnicz MD, PhD,
Corresponding Author
Oliwia Anna Segiet MD
Department of Histology and Embryology, Zabrze, Medical University of Silesia, Katowice, Poland
Corresponding author: O. Segiet, Department of Histology and Embryology in Zabrze, 41-808 Zabrze Rokitnica, ul. Jordana 19, Poland. E-mail: [email protected]Search for more papers by this authorMariusz Deska MD
Chair and Clinical Department of General Surgery, Bytom, Medical University of Silesia, Katowice, Poland
Search for more papers by this authorMarek Michalski PhD
Department of Histology and Embryology, Zabrze, Medical University of Silesia, Katowice, Poland
Search for more papers by this authorJacek Gawrychowski MD, PhD
Chair and Clinical Department of General Surgery, Bytom, Medical University of Silesia, Katowice, Poland
Search for more papers by this authorRomuald Wojnicz MD, PhD
Department of Histology and Embryology, Zabrze, Medical University of Silesia, Katowice, Poland
Search for more papers by this authorAbstract
Background
Primary hyperparathyroidism (HPT) is one of the most common endocrine disorders, defined by hypersecretion of parathormone. Primary HPT can be caused by adenoma, hyperplasia, and carcinoma. A great amount of mechanisms contribute to the pathogenesis of this disease, such as genetic predispositions because of the germline-inactivating mutations in the multiple endocrine neoplasia type 1 (MEN1) and HRPT2 tumor suppressor genes. Somatic mutations in these genes were found also in sporadic parathyroid neoplasias. Cell cycle regulators, growth factors, apoptosis-inducing ligands, death receptors, and other transmitter substances have also been implicated in the etiology of primary HPT. Parathyroid carcinoma is often misdiagnosed as parathyroid adenoma and long-term survival is conditioned by the extent of the primary surgical resection, therefore, of great interest is the discovery of definitive diagnostic markers for carcinoma. This article presents current state of knowledge of the molecular pathogenesis of primary HPT. © 2014 Wiley Periodicals, Inc. Head Neck, 2014 © 2014 Wiley Periodicals, Inc. Head Neck 37: 299-307, 2015
REFERENCES
- 1Adami S, Marcocci C, Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002; 17 Suppl 2: 18–23.
- 2Fraser WD. Hyperparathyroidism. Lancet 2009; 374: 145–158.
- 3Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995; 333: 234–240.
- 4Tfelt–Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005; 42: 35–70.
- 5Cavalier E, Daly AF, Betea D, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab 2010; 95: 3745–3749.
- 6Rubin MR, Silverberg SJ, D'Amour P, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem 2007; 53: 1470–1476.
- 7Caron P, Maiza JC, Renaud C, Cormier C, Barres BH, Souberbielle JC. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2009; 70: 533–538.
- 8Imanishi Y. Molecular pathogenesis of tumorigenesis in sporadic parathyroid adenomas. J Bone Miner Metab 2002; 20: 190–195.
- 9Árvai K, Nagy K, Barti–Juhász H, et al. Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma. Pathol Oncol Res 2012; 18: 607–614.
- 10DeLellis RA, Lloyd RV, Heitz PU. Pathology and genetics of the tumours of endocrine organs. In: RA DeLellis, RV Lloyd, PU Heitz, C Eng, editors. WHO classification of tumours. Lyon, France: IARC Press; 2006. pp 124–127.
- 11Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 2001; 136: 878–885.
- 12Arnold A, Marx SJ. Familial hyperparathyroidism (including MEN, FHH, and HPT-JT). In: CJ Rosen, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington DC: American Society for Bone and Mineral Research; 2008. pp 361–366.
- 13Schussheim DH, Skarulis MC, Agarwal SK, et al. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001; 12: 173–178.
- 14Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404–407.
- 15Agarwal SK, Guru SC, Heppner C, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999; 96: 143–152.
- 16Miedlich S, Krohn K, Lamesch P, Müller A, Paschke R. Frequency of somatic MEN1 gene mutations in monoclonal parathyroid tumours of patients with primary hyperparathyroidism. Eur J Endocrinol 2000; 143: 47–54.
- 17Uchino S, Noguchi S, Sato M, et al. Screening of the Men1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors. Cancer Res 2000; 60: 5553–5557.
- 18Scarpelli D, D'Aloiso L, Arturi F, et al. Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics. J Endocrinol Invest 2004; 27: 1015–1021.
- 19Vierimaa O, Villablanca A, Alimov A, et al. Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition. J Endocrinol Invest 2009; 32: 512–518.
- 20Dwight T, Nelson AE, Theodosopoulos G, et al. Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism. Am J Pathol 2002; 161: 1299–1306.
- 21Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008; 14: 36–46.
- 22Yokoyama A, Wang Z, Wysocka J, et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol Cell Biol 2004; 24: 5639–5649.
- 23Chen YX, Yan J, Keeshan K, et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci U S A 2006; 103: 1018–1023.
- 24Shen HC, Rosen JE, Yang LM, et al. Parathyroid tumor development involves deregulation of homeobox genes. Endocr Relat Cancer 2008; 15: 267–275.
- 25Howe JR, Norton JA, Wells SA Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 1993; 114: 1070–1077.
- 26Schuffenecker I, Virally–Monod M, Brohet R, et al. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab 1998; 83: 487–491.
- 27Gagel RF. Pheochromocytoma, multiple endocrine neoplasia type 2, and von Hippel–Lindau disease. N Engl J Med 1994; 330: 1090–1091.
- 28Jackson CE, Norum RA, Boyd SB, et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 1990; 108: 1006–1012; discussion 1012–1013.
- 29Szabó J, Heath B, Hill VM, et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 1995; 56: 944–950.
- 30Wassif WS, Farnebo F, Teh BT, et al. Genetic studies of a family with hereditary hyperparathyroidism-jaw tumour syndrome. Clin Endocrinol (Oxf) 1999; 50: 191–196.
- 31Haven CJ, Wong FK, van Dam EW, et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism–jaw tumor syndrome. J Clin Endocrinol Metab 2000; 85: 1449–1454.
- 32Teh BT, Farnebo F, Twigg S, et al. Familial isolated hyperparathyroidism maps to the hyperparathyroidism–jaw tumor locus in 1q21-q32 in a subset of families. J Clin Endocrinol Metab 1998; 83: 2114–2120.
- 33Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome. Nat Genet 2002; 32: 676–680.
- 34Lin L, Zhang JH, Panicker LM, Simonds WF. The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene. Proc Natl Acad Sci U S A 2008; 105: 17420–17425.
- 35Lin L, Czapiga M, Nini L, Zhang JH, Simonds WF. Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism–jaw tumor syndrome enhances its proapoptotic function. Mol Canc Res 2007; 5: 183–193.
- 36Kim HK, Oh YL, Kim SH, et al. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma. Head Neck 2012; 34: 201–206.
- 37Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res 2004; 10: 6629–6637.
- 38Juhlin CC, Haglund F, Obara T, Arnold A, Larsson C, Höög A. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours. Virchows Arch 2011; 459: 47–53.
- 39Juhlin CC, Nilson IL, Johansson K, et al. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 2010; 21: 166–177.
- 40Wang O, Wang CY, Shi J, et al. Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors. Chin Med J (Engl) 2012; 125: 2895–2901.
- 41Shattuck TM, Välimäki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003; 349: 1722–1729.
- 42Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003; 40: 657–663.
- 43Gill AJ, Clarkson A, Gimm O, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 2006; 30: 1140–1149.
- 44Wassif WS, Moniz CF, Friedman E, et al. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 1993; 77: 1485–1489.
- 45Miedlich S, Lohmann T, Schneyer U, Lamesch P, Paschke R. Familial isolated primary hyperparathyroidism—a multiple endocrine neoplasia type 1 variant? Eur J Endocrinol 2001; 145: 155–160.
- 46Tfelt–Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005; 42: 35–70.
- 47Brown EM, Pollak M, Seidman CE, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med 1995; 333: 234–240.
- 48Marx SJ, Attie MF, Levine MA, Spiegel AM, Downs RW Jr, Lasker RD. The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine (Baltimore) 1981; 60: 397–412.
- 49Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 1996; 81: 1736–1739.
- 50Hemmer S, Wasenius VM, Haglund C, et al. Deletion of 11q23 and cyclin D1 overexpression are frequent aberrations in parathyroid adenomas. Am J Pathol 2001; 158: 1355–1362.
- 51Tominaga Y, Tsuzuki T, Uchida K, et al. Expression of PRAD1/cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999; 55: 1375–1383.
- 52Vasef MA, Brynes RK, Sturm M, Bromley C, Robinson RA. Expression of cyclin D1 in parathyroid carcinomas, adenomas, and hyperplasias: a paraffin immunohistochemical study. Mod Pathol 1999; 12: 412–416.
- 53Hosokawa Y, Tu T, Tahara H, Smith AP, Arnold A. Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancer Lett 1995; 93: 165–170.
- 54Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2009; 8: 253–267.
- 55Szende B, Arvai K, Peták I, Nagy K, Végsô G, Perner F. Changes in gene expression in the course of proliferative processes in the parathyroid gland [in Hungarian]. Magy Onkol 2006; 50: 137–140.
- 56Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994; 330: 757–761.
- 57Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 1996; 45: 195–200.
- 58Dotzenrath C, Teh BT, Farnebo F, et al. Allelic loss of the retinoblastoma tumor suppressor gene: a marker for aggressive parathyroid tumors? J Clin Endocrinol Metab 1996; 81: 3194–3196.
- 59Cetani F, Pardi E, Viacava P, et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 2004; 60: 99–106.
- 60Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000; 182: 311–322.
10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9 CAS PubMed Web of Science® Google Scholar
- 61Alò PL, Visca P, Mazzaferro S, et al. Immunohistochemical study of fatty acid synthase, Ki67, proliferating cell nuclear antigen, and p53 expression in hyperplastic parathyroids. Ann Diagn Pathol 1999; 3: 287–293.
- 62Stojadinovic A, Hoos A, Nissan A, et al. Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis. Hum Pathol 2003; 34: 54–64.
- 63Lloyd RV, Carney JA, Ferreiro JA, et al. Immunohistochemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas. Endocr Pathol 1995; 6: 279–287.
- 64Demiralay E, Altaca G, Demirhan B. Morphological evaluation of parathyroid adenomas and immunohistochemical analysis of PCNA and Ki-67 proliferation markers. Turk Patoloji Derg 2011; 27: 215–220.
- 65Shivji KK, Kenny MK, Wood RD. Proliferating cell nuclear antigen is required for DNA excision repair. Cell 1992; 69: 367–374.
- 66Xiong Y, Zhang H, Beach D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992; 71: 505–514.
- 67Yamaguchi S, Yachiku S, Morikawa M. Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism. J Clin Endocrinol Metab 1997; 82: 2681–2688.
- 68Loda M, Lipman J, Cukor B, Bur M, Kwan P, DeLellis RA. Nodular foci in parathyroid adenomas and hyperplasias: an immunohistochemical analysis of proliferative activity. Hum Pathol 1994; 25: 1050–1056.
- 69Ohta K, Manabe T, Katagiri M, Harada T. Expression of proliferating cell nuclear antigens in parathyroid glands of renal hyperparathyroidism. World J Surg 1994; 18: 625–628; discussion 628–629.
- 70Hofstädter F, Knüchel R, Rüschoff J. Cell proliferation assessment in oncology. Virchows Arch 1995; 427: 323–341.
- 71Toschi L, Bravo R. Changes in cyclin/proliferating cell nuclear cell antigen distribution during DNA repair synthesis. J Cell Biol 1988; 107: 1623–1628.
- 72Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990; 162: 285–294.
- 73Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676.
- 74Lambert D, Eaton CL, Harrison BJ. Fibroblast growth factors and their receptors in parathyroid disease. World J Surg 1998; 22: 520–525.
- 75Wilkie AO, Morriss–Kay GM, Jones EY, Heath JK. Functions of fibroblast growth factors and their receptors. Curr Biol 1995; 5: 500–507.
- 76Schuster N, Krieglstein K. Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res 2002; 307: 1–14.
- 77Tahimic CG, Wang Y, Bikle DD. Anabolic effects of IGF-1 signaling on the skeleton. Front Endocrinol (Lausanne) 2013; 4: 6.
- 78Harvey AK, Yu XP, Frolik CA, Chandrasekhar S. Parathyroid hormone-(1–34) enhances aggrecan synthesis via an insulin-like growth factor-I pathway. J Biol Chem 1999; 274: 23249–23255.
- 79Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 2001; 142: 4349–4356.
- 80Wang Y, Nishida S, Boudignon BM, et al. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res 2007; 22: 1329–1337.
- 81Wang Y, Elalieh H, Bikle D. IGF-I signaling regulates the interaction of osteoblasts and osteoclasts via the RANKL/RANK and ephrin B2/EphB4 signaling pathways. J Bone Miner Res 2010; 25(Suppl 1): 101.
- 82Tanaka R, Tsushima T, Murakami H, Shizume K, Obara T. Insulin-like growth factor I receptors and insulin-like growth factor-binding proteins in human parathyroid tumors. World J Surg 1994; 18: 635–641; discussion 641–642.
- 83Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ. Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 2000; 10: 1201–1204.
- 84Liu FT, Hsu DK, Zuberi RI, Kuwabara IChi EY, Henderson WR Jr. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. Am J Pathol 1995; 147: 1016–1028.
- 85Abdel–Aziz HO, Murai Y, Takasaki I, et al. Targeted disruption of the galectin-3 gene results in decreased susceptibility to NNK-induced lung tumorigenesis: an oligonucleotide microarray study. J Cancer Res Clin Oncol 2008; 134: 777–788.
- 86van Veldhuisen DJ, Lok DJ, Damman K, et al. Clinical and prognostic value of galectin-3, a novel fibrosis-associated biomarker, in patients with chronic heart failure. J Card Fail 2009; 15: 814.
10.1016/j.cardfail.2009.10.013 Google Scholar
- 87DeFilippi C, Christenson R, Shah R, et al. Clinical validation of a novel assay for galectin-3 for risk assessment in acutely destabilized heart failure. J Card Fail 2009; 15: 9.
10.1016/j.cardfail.2009.06.405 Google Scholar
- 88Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000; 18: 1967–1979.
- 89Miyoshi Y, Ando H, Nagase H, et al. Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci U S A 1992; 89: 4452–4456.
- 90Juhlin CC, Haglund F, Villablanca A, et al. Loss of expression for the Wnt pathway components adenomatous polyposis coli and glycogen synthase kinase 3-beta in parathyroid carcinomas. Int J Oncol 2009; 34: 481–492.
- 91Svedlund J, Aurén M, Sundström M, et al. Aberrant WNT/β-catenin signaling in parathyroid carcinoma. Mol Cancer 2010; 9: 294.
- 92Sullivan BT, Cherry JA, Sakamoto H, Henkes LE, Townson DH, Rueda BR. Cytokeratin 18 expression inhibits cytokine-induced death of cervical cancer cells. Int J Gynecol Cancer 2010; 20: 1474–1481.
- 93Fendrich V, Waldmann J, Feldmann G, et al. Unique expression pattern of the EMT markers Snail, Twist and E-cadherin in benign and malignant parathyroid neoplasia. Eur J Endocrinol 2009; 160: 695–703.
- 94Van den Bossche J, Malissen B, Mantovani A, De Baetselier P, Van Ginderachter JA. Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood 2012; 119: 1623–1633.
- 95Barrallo–Gimeno A, Nieto MA. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005; 132: 3151–3161.
- 96Fendrich V, Maschuw K, Waldmann J, et al. Epithelial-mesenchymal transition is a critical step in tumorgenesis of pancreatic neuroendocrine tumors. Cancers (Basel) 2012; 4: 281–294.
- 97Muenst S, Däster S, Obermann EC, et al. Nuclear expression of snail is an independent negative prognostic factor in human breast cancer. Dis Markers 2013; 35: 337–344.
- 98Yang J, Mani SA, Donaher JL, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927–939.
- 99Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A 1986; 83: 3500–3504.
- 100Hendy GN, Bevan S, Mattei MG, Mouland AJ. Chromogranin A. Clin Invest Med 1995; 18: 47–65.
- 101Howell VM, Gill A, Clarkson A, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 2009; 94: 434–441.
- 102Ding D, Zhou J, Wang M, Cong YS. Implications of telomere-independent activities of telomerase reverse transcriptase in human cancer. FEBS J 2013; 280: 3205–3211.
- 103Osawa N, Onoda N, Kawajiri H, et al. Diagnosis of parathyroid carcinoma using immunohistochemical staining against hTERT. Int J Mol Med 2009; 24: 733–741.
- 104Weiss MM, Hermsen MA, Meijer GA, et al. Comparative genomic hybridisation. Mol Pathol 1999; 52: 243–251.
- 105Agarwal SK, Schröck E, Kester MB, et al. Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet 1998; 106: 30–36.
- 106Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, Arnold A. Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 1998; 83: 1766–1770.
- 107Kytölä S, Farnebo F, Obara T, et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 2000; 157: 579–586.
- 108Haven CJ, van Puijenbroek M, Karperien M, Fleuren GJ, Morreau H. Differential expression of the calcium sensing receptor and combined loss of chromosome 1p and 11q in parathyroid carcinoma. J Pathol 2004; 202: 86–94.
- 109Erickson LA, Jalal SM, Harwood A, Shearer B, Jin L, Lloyd RV. Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization. Am J Surg Pathol 2004; 28: 578–584.
- 110Välimäki S, Forsberg L, Farnebo LO, Larsson C. Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol 2002; 21: 727–735.
Citing Literature
